Group: Management

Debra Marshall, MD, FACC

Dr. Debra Marshall is the Chief Medical Officer at ARCA Biopharma. Dr. Marshall joined ARCA in 2016 and has spent more than 20 years dedicated to cardiovascular drug development. Through her career in pharma and biotech she advanced to roles of senior leadership that involved development and approval of medicines for Heart failure, Hypertension, Acute Coronary Syndromes and Dyslipidemias. Prior to joining ARCA, she served as an Executive Medical Director in the Cardiovascular Therapeutic Area at Amgen, Senior Medical Director in Cardio-Metabolism at Genentech, Global Senior Medical Director for the CV/Acute Care team at Lilly and Associate Medical Director for CV Medical Affairs at Novartis Pharmaceutical Corporation.

Dr. Marshall holds a B.S. in Chemistry and an M.D. from the University of California, Los Angeles. She completed an internship in Internal Medicine at the University of Pennsylvania, Philadelphia and Internal Medicine residency at St Vincent Hospital in Portland, Oregon. Following a cardiology fellowship at the Oregon Health Sciences University, she served as an Assistant Professor at the University of Virginia School of Medicine in Charlottesville, an Associate Professor at the University of Los Angeles School of Medicine and held positions in private cardiology practices. Dr. Marshall has been an NIH and AHA grant recipient, was awarded a US Patent and has authored numerous scientific and clinical publications. She earned board certifications in Internal Medicine, Cardiovascular Diseases, Interventional Cardiology and Nuclear Cardiology.

Christopher D. Ozeroff

Mr. Ozeroff is a co-founder of ARCA. Mr. Ozeroff has served as the Company’s Senior Vice President, General Counsel and Secretary since 2009, has served as the Company’s General Counsel and Secretary since the Company’s founding, and has also served as Executive Vice President, Business Development from 2004 to 2009. Prior to joining the Company, Mr. Ozeroff was a partner with the law firm of Hogan & Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings, and licensing. Mr. Ozeroff completed his undergraduate degree at Stanford University and his law degree at the University of Chicago Law School.

C. Jeff Dekker

Mr. Dekker has served as the Company’s Chief Financial Officer since May 2021. Prior to joining the Company, Mr. Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller.  Before joining GlobeImmune, Mr. Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.

Thomas A. Keuer

Mr. Keuer has served as the Company’s Chief Operating Officer since December 2014. Mr. Keuer served as the Company’s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining the Company, Mr. Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr. Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr. Keuer served as the VP of Operations for Somatogen, Inc. Mr. Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.

Michael R. Bristow

Dr. Bristow was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr. Bristow has also served as the Company’s President and Chief Executive Officer since July 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the Company’s Chief Science and Medical Officer from November 2006 to July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. We believe Dr. Bristow is an appropriate member of the Company’s Board of Directors given his extensive experience and expertise as a cardiologist, medical researcher and drug developer in the field of cardiovascular medicine, and heart failure specifically, and his experience as a founder and manager of a cardiovascular-focused, public pharmaceutical company. Dr. Bristow also has extensive experience with, and knowledge of, ARCA’s business, as the founder and former Chief Science and Medical Officer of the Company, and the current President and Chief Executive Officer of ARCA, and as a member of the Board of Directors of ARCA since the founding of the Company. Dr. Bristow holds a M.D. and Ph.D. from the University of Illinois.